Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Silodosin for bladder emptying problems in women with multiple sclerosis
2015-002820-20Phase 3Terminated
- Sponsor
- Erasmus MC
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of silodosin in neurogenic bladder and multiple sclerosis (MS), sponsored by Erasmus MC. Primary endpoint: Residual urine volume change at 6 weeks. Started Jan 2016; status: terminated.
02
Drugs
silodosin
03
Conditions
neurogenic bladdermultiple sclerosis (MS)
Beyond the preview
Go deeper on 2015-002820-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002820-20.